Cargando…

Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging

Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogele, Daniel, Schmidt, Stefan A., Gnutzmann, Daniel, Thaiss, Wolfgang M., Ettrich, Thomas J., Kornmann, Marko, Beer, Meinrad, Juchems, Markus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486652/
https://www.ncbi.nlm.nih.gov/pubmed/37685279
http://dx.doi.org/10.3390/diagnostics13172741
_version_ 1785103057423433728
author Vogele, Daniel
Schmidt, Stefan A.
Gnutzmann, Daniel
Thaiss, Wolfgang M.
Ettrich, Thomas J.
Kornmann, Marko
Beer, Meinrad
Juchems, Markus S.
author_facet Vogele, Daniel
Schmidt, Stefan A.
Gnutzmann, Daniel
Thaiss, Wolfgang M.
Ettrich, Thomas J.
Kornmann, Marko
Beer, Meinrad
Juchems, Markus S.
author_sort Vogele, Daniel
collection PubMed
description Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography–computed tomography (PET/CT) are available for both localization and staging of NEN. Nuclear medical imaging methods with somatostatin analogs are of great importance since radioactively labeled receptor ligands make tumors visible with high sensitivity. CT and MRI have high detection rates for GEP-NEN and have been further improved by developments such as diffusion-weighted imaging. However, nuclear medical imaging methods are superior in detection, especially in gastrointestinal NEN. It is important for radiologists to be familiar with NEN, as it can occur ubiquitously in the abdomen and should be identified as such. Since GEP-NEN is predominantly hypervascularized, a biphasic examination technique is mandatory for contrast-enhanced cross-sectional imaging. PET/CT with somatostatin analogs should be used as the subsequent method.
format Online
Article
Text
id pubmed-10486652
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104866522023-09-09 Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging Vogele, Daniel Schmidt, Stefan A. Gnutzmann, Daniel Thaiss, Wolfgang M. Ettrich, Thomas J. Kornmann, Marko Beer, Meinrad Juchems, Markus S. Diagnostics (Basel) Review Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography–computed tomography (PET/CT) are available for both localization and staging of NEN. Nuclear medical imaging methods with somatostatin analogs are of great importance since radioactively labeled receptor ligands make tumors visible with high sensitivity. CT and MRI have high detection rates for GEP-NEN and have been further improved by developments such as diffusion-weighted imaging. However, nuclear medical imaging methods are superior in detection, especially in gastrointestinal NEN. It is important for radiologists to be familiar with NEN, as it can occur ubiquitously in the abdomen and should be identified as such. Since GEP-NEN is predominantly hypervascularized, a biphasic examination technique is mandatory for contrast-enhanced cross-sectional imaging. PET/CT with somatostatin analogs should be used as the subsequent method. MDPI 2023-08-23 /pmc/articles/PMC10486652/ /pubmed/37685279 http://dx.doi.org/10.3390/diagnostics13172741 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vogele, Daniel
Schmidt, Stefan A.
Gnutzmann, Daniel
Thaiss, Wolfgang M.
Ettrich, Thomas J.
Kornmann, Marko
Beer, Meinrad
Juchems, Markus S.
Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
title Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
title_full Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
title_fullStr Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
title_full_unstemmed Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
title_short Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
title_sort gastroenteropancreatic neuroendocrine tumors—current status and advances in diagnostic imaging
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486652/
https://www.ncbi.nlm.nih.gov/pubmed/37685279
http://dx.doi.org/10.3390/diagnostics13172741
work_keys_str_mv AT vogeledaniel gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT schmidtstefana gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT gnutzmanndaniel gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT thaisswolfgangm gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT ettrichthomasj gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT kornmannmarko gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT beermeinrad gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging
AT juchemsmarkuss gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging